Christoph D. Spinner

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner et al. · JAMA · 2020 · 1.3K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +9

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Georg Härter, Christoph D. Spinner, Julia Roider et al. · Infection · 2020 · 246 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV

Christian Hoffmann, José L. Casado, Georg Härter et al. · HIV Medicine · 2020 · 166 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17